New eye ointment aims to soothe dry, burning eyes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years old * Ocular Surface Disease Index (OSDI) ≧ 16 * Median of three consecutive non-invasive tear film break-up time (NIBUT) test results less than or equal to 10 seconds in at least one eye * Willingness to apply the medical device under evaluation as per Instructions for Use (IfU) during the entire study duration (i.e., 33 ± 3 days) * Willingness to undergo a follow-up visit at day 15 ± 3 and 33 ± 3 after enrolment * Good understanding of written and oral speaking languages used at the centre where the study will be carried out Exclusion Criteria: * Known hypersensitivity (allergy) to any of the ingredients of Vit-A-Vision: vaseline, paraffin, adeps lanae, vitamin A palmitate, dexpanthenol, α-Tocopherol acetate or cetylstearyl alcohol. * Severe forms of dry eye syndrome with OSDI \> 55 * Not willing to discontinue contact lens use during the study period * Refractive surgery within the last 12 months and/or any other ocular surgery or ocular trauma/injury within the last 4 months * Acute inflammatory or ocular surface disease, Sjögren's Syndrome (autoimmune disease), Stevens-Johnson Syndrome, ocular pemphigoid, and radiation-induced dry eye. * Use of systemic medication that could affect vision or dry eye, including essential fatty acids, unless dose has been constant for more than 3 months and is not expected to change during the study * Systemic concomitant medications: * Corticosteroids within 2 months before enrolment and for the whole study period and / or * Tetracyclines within 1 month before selection and for the whole study period. * Vitamin A supplements intake * Use of topical ophthalmic medication during the study or within 2 weeks prior to the first visit, other than artificial tears * Use of topical cyclosporine within 3 months prior to the first visit * Use of other eye drops/sprays (based on liposomic and/or oily products) during the present investigation * Abnormality of the nasolacrimal drainage apparatus * Permanent occlusion of lacrimal puncta in any eye * Use of temporary punctal plug in any eye within 2 months before the selection visit * Previous enrolment into the current investigation * Patients who participated in any other clinical trial within the last 30 days before selection * Children, pregnant and breastfeeding women * Participants under the influence of excessive alcohol, narcotics or benzodiazepines * Other diseases or characteristics judged by the investigator to be incompatible with the frequent assessments needed in this study or with reliable instillation of the products (for example: mental or physical incapacity, language comprehension, psychological disorders, dementia, geographical localisation, etc...). * Individuals who are deprived of liberty pursuant to an administrative order or court order or approval